<DOC>
	<DOCNO>NCT02893124</DOCNO>
	<brief_summary>HBeAg-negative chronic hepatitis B ( CHB ) patient low Level HBsAg history drug resistance suboptimal/partial virological response enrol . After give informed consent , patient treat nucleoside analog ( ) ( NAs ) day weekly subcutaneous injection alfa-2a 180 micrograms/week peginterferon alfa-2b 80 micrograms/week 12 week . 12 week later , NAs stop , patient treat weekly subcutaneous injection alfa-2a 180 micrograms/week peginterferon alfa-2b 80 micrograms/week . Treatment endpoint HBsAg loss ( ＜0.05 IU/mL ) .</brief_summary>
	<brief_title>The Optimizing Treatment Peginterferon ( PEG IFN ) Alpha Chronic Hepatitis B Virus Patients With Low Level HBsAg</brief_title>
	<detailed_description>It estimate 400 million people infected hepatitis B virus ( HBV ) globally . HBeAg-negative CHB patient low Level HBsAg history drug resistance suboptimal/partial virological response enrol out-patient department 3rd Affiliated Hospital Sun Yat-sen University . All HBsAg positive anti-HBs negative 6 month HBV DNA &lt; 100 IU/mL HBsAg level &lt; 1000 IU/mL . All patient liver disease contraindication interferon therapy . After give informed consent , patient treat NAs day weekly subcutaneous injection alfa-2a 180 micrograms/week peginterferon alfa-2b 80 micrograms/week 12 week . 12 week later , NAs stop , patient treat weekly subcutaneous injection alfa-2a 180 micrograms/week peginterferon alfa-2b 80 micrograms/week . The use immune suppressive regulatory drug antiviral drug prohibit course study . In study , treatment endpoint HBsAg loss ( ＜0.05 IU/mL ) .Anti-HBs positive ( ＞10 milli-International unit ) ( mIU/mL ) define seroconversion . Depending decline HBsAg level , treatment either continue prolonged period ( 96 week ) endpoint achieve , terminate case nonresponse .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>1 . CHB patient receive single NAs 12 month history NAs drug resistance suboptimal/partial virological response . 2 . Hepatitis B e antigen ( HBeAg ) negative . 3 . Hepatitis B surface antigen ( HBsAg ) positive &lt; 1000 IU/mL . 4 . Hepatitis B virus DNA &lt; 100 IU/mL . 1 . Patients liver cirrhosis , Hepatocellular Carcinoma alpha feto protein ( AFP ) &gt; 2 upper limit normal ( ULN ) malignancy . 2 . Patients factor cause liver disease . 3 . Pregnant lactating woman . 4 . Patients concomitant HIV infection congenital immune deficiency disease . 5 . Patients diabetes , autoimmune disease . 6 . Patients important organ dysfunction . 7 . Patients serious complication ( e.g. , infection , hepatic encephalopathy , hepatorenal syndrome , gastrointestinal bleeding . ) 8 . Patients receive antineoplastic immunomodulatory therapy past 12 month . 9 . Patients previous use IFN anti hepatitis B virus treatment . 10 . Patients ca n't come back clinic followup schedule .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>chronic hepatitis B</keyword>
</DOC>